Guidelines for Ordering and Interpreting Plasma Homocysteine Tests
Pre‑analytical Requirements
- Obtain a fasting (8–12 hour) blood sample before testing to avoid post‑prandial variation. 1
- Collect blood in a chilled tube (EDTA or heparin plasma preferred) and place the tube on ice immediately after draw. 1, 2, 3
- Centrifuge and separate plasma within 30 minutes of collection; then freeze the plasma right away. Frozen plasma remains stable for months. 1, 2, 3
- Proper sample handling is essential because homocysteine is released from red blood cells at room temperature, leading to falsely elevated results if the sample is not iced promptly. 1, 2
Laboratory Selection
- Send the specimen to a specialized laboratory that measures total homocysteine (tHcy), not just free homocysteine, because roughly 70 % of plasma homocysteine is protein‑bound. 1, 3
- Total homocysteine assays require a reduction step (e.g., dithiothreitol or tri‑n‑butylphosphine) to liberate protein‑bound homocysteine before quantification. 1, 3
Interpretation of Results
| Category | Approximate tHcy range (μmol/L) | Clinical implication |
|---|---|---|
| Normal | 5 – 15 | No immediate concern |
| Mild elevation | 10 – 15 | May indicate a graded increase in vascular risk |
| Hyperhomocysteinemia | > 15 | Independent risk factor for premature vascular disease |
- Normal plasma homocysteine values are generally 5–15 μmol/L. 1, 3, 4
- Levels of 10–15 μmol/L are considered mildly elevated and can reflect a graded rise in vascular risk. 1, 2
- Values > 15 μmol/L define hyperhomocysteinemia, an established independent risk factor for early‑onset coronary, cerebral, or peripheral vascular disease. 1, 2
Common Pitfalls
- Failure to ice the sample immediately is the most frequent cause of spuriously high homocysteine results; even a 30–60 minute delay at room temperature can markedly increase measured levels. 1
- Sending whole blood instead of separated, frozen plasma compromises accuracy and should be avoided. 1
Clinical Indications
- Measure plasma homocysteine when assessing risk factors for premature vascular disease (coronary, cerebral, peripheral), venous thrombosis, or when an inherited disorder of homocysteine metabolism is suspected. 1, 2
All facts are supported by the cited references and reflect the current evidence base.